Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
May 03, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Global Anterior Uveitis Treatment Market (2020 to 2026) - Featuring Mylan, Allergan & Cadila Pharmaceuticals Among Others
February 22, 2021 05:48 ET
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Anterior uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global anterior uveitis treatment...
Worldwide Uveitis Treatment Industry to 2026 - Key Motivators, Restraints and Opportunities
February 22, 2021 05:43 ET
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global uveitis treatment market is projected...
Outlook on the Uveitis Treatment Global Market to 2025 - Impact of COVID-19 on the Market
December 18, 2020 05:23 ET
|
Research and Markets
Dublin, Dec. 18, 2020 (GLOBE NEWSWIRE) -- The "Uveitis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development
August 01, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...